 |
|
|
| |
Sofosbuvir/Velpatasvir (S/V) For The Treatment Of
HCV Infection Among Vulnerable Inner-city (PWID) Residents:
Extending The Results Of Clinical Trial Part 2
|
| |
| |
We note median age (range) 46 (20-81) years, 29%female, 56.4% genotype (GT) 1 , 21.2%cirrhotic, 84.6% active opiate users at the time of initiation of therapy. The next most commonly used drugs were amphetamines and crack-cocaine (69%, 52% respectively).
By ITT/mITT analysis, SVR rate is 85.1 % (171/201) and 95.5% (171/179) respectively. In the context of an opioid crisis with 7 documented deaths/day in the province of British Columbia, we have observed only 2 deaths in the treated study population from time of initial identification at CPC events.
EASL 2023 June 21-24 Vienna
|
| |
|
|
|
|
|
